{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Participants were planned to receive PF-07263689 in combination with sasanlimab at the preliminary combination recommended Phase 2 dose from Part 1B.","id":"OG000","title":"Part 2: PF-07263689 + Sasanlimab"}],"populationDescription":"Data was not collected as no participants were enrolled in Part 2 of the study due to study termination.","reportingStatus":"POSTED","timeFrame":"30, 45 and 60 days after the last PF-07263689 dose","title":"Part 2: Viral Titers in Saliva, Urine and Skin Swabs During 30, 45 and 60 Days After the Last PF-07263689 Dose","type":"SECONDARY"}